Medical Foods for Inborn Errors of Metabolism Market Opportunities and Strategies to 2034

This report describes and explains the medical foods for inborn errors of metabolism market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global medical foods for inborn errors of metabolism market reached a value of nearly $3.07 billion in 2024, having grown at a compound annual growth rate (CAGR) of 9.94% since 2019. The market is expected to grow from $3.07 billion in 2024 to $5.5 billion in 2029 at a rate of 12.34%. The market is then expected to grow at a CAGR of 11.50% from 2029 and reach $9.48 billion in 2034.

Growth in the historic period resulted from the rising detection of genetic disorders, expanding patient access to healthcare services, expanding healthcare infrastructure and growth in healthcare expenditure globally. Factor that negatively affected growth in the historic period was high cost of medical foods.

Going forward, increasing aging population, rising detection of inborn errors of metabolism, increasing focus on personalized nutrition, growing awareness and detection of metabolic disorders and supportive government healthcare initiatives will drive the growth. Factor that could hinder the growth of the medical foods for inborn errors of metabolism market in the future include regulatory classification confusion.

The global medical foods for inborn errors of metabolism market is fairly fragmented, with a large number of players operating in the market. The top ten competitors in the market made up 21.88% of the total market in 2023. Fresenius Kabi was the largest competitor with a 3.21% share of the market, followed by Nestlé S.A. with 3.18%, Abbott Laboratories Inc. with 3.00%, Mount Sinai Health System Inc. with 2.98%, Danone SA with 2.72%, Ajinomoto Co. Inc. with 2.17%, Reckitt Benckiser Group plc (Mead Johnson & Company, LLC) with 1.91%, Galen Limited with 1.36%, BC Children's Hospital with 0.69% and Metagenics Inc. with 0.65%.

The medical foods for inborn errors of metabolism market is segmented by product into amino acid-based medical foods, glytactin with GMP amino acid-modified infant formula with iron, low-calcium/vitamin D-free infant formula with iron, low protein food and other products. The amino acid-based medical foods market was the largest segment of the medical foods for inborn errors of metabolism market segmented by product, accounting for 47.06% or $1.44 billion of the total in 2024. Going forward, the glytactin with GMP amino acid-modified infant formula with iron segment is expected to be the fastest growing segment in the medical foods for inborn errors of metabolism market segmented by product, at a CAGR of 13.49% during 2024-2029.

The medical foods for inborn errors of metabolism market is segmented by forms into powder, liquids, gels and other forms. The powder market was the largest segment of the medical foods for inborn errors of metabolism market segmented by forms, accounting for 51.26% or $1.57 billion of the total in 2024. Going forward, the gels segment is expected to be the fastest growing segment in the medical foods for inborn errors of metabolism market segmented by forms, at a CAGR of 13.92% during 2024-2029.

The medical foods for inborn errors of metabolism market is segmented by distribution channel into retail pharmacies, hospital pharmacies, drugs stores, online pharmacies and other distribution channels. The retail pharmacies market was the largest segment of the medical foods for inborn errors of metabolism market segmented by distribution channel, accounting for 34.23% or $1.05 billion of the total in 2024. Going forward, the online pharmacies segment is expected to be the fastest growing segment in the medical foods for inborn errors of metabolism market segmented by distribution channel, at a CAGR of 14.22% during 2024-2029.

The medical foods for inborn errors of metabolism market is segmented by diseases into phenylketonuria (PKU), organic acidurias, homocystinuria, disorders of leucine metabolism, glutaric acidemia type I renal disease and other diseases. The phenylketonuria (PKU) market was the largest segment of the medical foods for inborn errors of metabolism market segmented by diseases, accounting for 37.27% or $1.14 billion of the total in 2024. Going forward, the phenylketonuria (PKU) segment is expected to be the fastest growing segment in the medical foods for inborn errors of metabolism market segmented by diseases, at a CAGR of 13.99% during 2024-2029.

The medical foods for inborn errors of metabolism market is segmented by age group into infants, weaning, adolescent and adults. The infants market was the largest segment of the medical foods for inborn errors of metabolism market segmented by age group, accounting for 42.06% or $1.29 billion of the total in 2024. Going forward, the weaning segment is expected to be the fastest growing segment in the medical foods for inborn errors of metabolism market segmented by age group, at a CAGR of 13.61% during 2024-2029.

North America was the largest region in the medical foods for inborn errors of metabolism market, accounting for 50.02% or $1.53 billion of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the medical foods for inborn errors of metabolism market will be Asia Pacific and Middle East where growth will be at CAGRs of 14.40% and 13.73% respectively. These will be followed by Africa and South America where the markets are expected to grow at CAGRs of 13.10% and 12.76% respectively.

The top opportunities in the medical foods for inborn errors of metabolism market segmented by product will arise in the amino acid-based medical foods segment, which will gain $1.15 billion of global annual sales by 2029. The top opportunities in the medical foods for inborn errors of metabolism market segmented by forms will arise in the powder segment, which will gain $1.18 billion of global annual sales by 2029. The top opportunities in the medical foods for inborn errors of metabolism market segmented by distribution channel will arise in the retail pharmacies segment, which will gain $891.85 million of global annual sales by 2029. The top opportunities in the medical foods for inborn errors of metabolism market segmented by diseases will arise in the phenylketonuria (PKU) segment, which will gain $1.06 billion of global annual sales by 2029. The top opportunities in the medical foods for inborn errors of metabolism market segmented by age group will arise in the infants segment, which will gain $1.03 billion of global annual sales by 2029. The medical foods for inborn errors of metabolism market size will gain the most in the USA at $996.11 million.

Market-trend-based strategies for the medical foods for inborn errors of metabolism market include focus on developing innovative products, including patient registry platforms, to enhance personalized treatment approaches and improve patient outcomes, focus on developing innovative products, such as low-phenylalanine amino acid foods, to address the nutritional needs of patients with metabolic disorders and focus on developing innovative products, including tyrosinemia tablets, to address unmet clinical needs and improve patient outcomes.

Player-adopted strategies in the medical foods for inborn errors of metabolism market include focus on strengthening operational capabilities through strategic partnerships and focus on strengthening operational capabilities through new launches.

To take advantage of the opportunities, the analyst recommends the medical foods for inborn errors of metabolism companies to focus on innovative patient registry platforms, focus on innovative low-phenylalanine products, focus on innovative tyrosinemia products, focus on glytactin with GMP amino acid-modified infant formula, focus on gel-based medical foods, focus on phenylketonuria (PKU) market, expand in emerging markets, continue to focus on developed markets, provide competitively priced offerings, continue to use B2C promotions, participate in trade shows and events, focus on online pharmacies for growth, focus on the infants market for growth and focus on increasing aging population.

Major Market Trends

• Advancements in Personalized Treatment for Inborn Errors of Metabolism Through Patient Registry Platforms
• New Amino Acid-Based Medical Food Launched for Phenylketonuria Management
• Innovative Tyrosinemia Tablets Launched to Address Unmet Needs in Metabolic Disorder Management

Key Mergers and Acquisitions

• Otsuka Pharmaceutical Acquired Jnana Therapeutics to Expand Metabolic Disorder Portfolio